UNSPSC 51161723: Almitrine dimesilate

This classification denotes a cns stimulant, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6RY6V6XM8T. European Medicines Agency schedules Almitrine dimesilate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00363MIG. Almitrine dimesilate generally arises in the molecular formula C26H29F2N7.2CH4O3S. The term 'almitrine dimesilate' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule almitrine dimesilate under HS 29336980 and SITC 51576.

SMILES: CS(=O)(=O)O.CS(=O)(=O)O.C=CCNC1NC(NC(N1)N2CCN(CC2)C(C3CCC(CC3)F)C4CCC(CC4)F)NCC=C.

UNSPSC 51161723 Almitrine dimesilate is a Commodity code that in practice covers pharmaceutical procurement by state and local health agencies, though the recent opportunities tagged under this code reveal a substantial scope mismatch — the opportunities solicited are for naloxone, on-site pharmacy services, direct-to-manufacturer prescription programs, and generic multi-source pharmaceuticals, none of which align with almitrine dimesilate (a respiratory stimulant) as a specific product line. State and local buyers under this code family are health departments, county government clinics, state health and human services commissions, and cooperative purchasing alliances administering multi-jurisdictional pharmaceutical contracts. The work includes both procurement of specific pharmaceutical products for distribution and the contracting of pharmacy benefit management or clinical pharmacy services to support employee health plans and community health initiatives.

Recent activity spans Florida, Georgia, Texas, and Minnesota. Seminole County, Florida issued an IFB (IFB60459723LAS, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option. Hall County, Georgia released an RFQ/P #47-010 (due June 4, 2026) for on-site pharmacy services at its Family Health Center Clinic serving approximately 3,000 enrolled individuals, with technical qualifications weighted at 80 percent and cost at 20 percent, an initial one-year term beginning January 1, 2027, and four optional one-year renewals. The Texas Health and Human Services Commission issued a Request for Information (RFI No. HHS0017013, posted April 3, 2026) to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered through the Minnesota Department of Administration, released an RFP (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers, with contract effectiveness set for July 1, 2026, and evaluation weighted 75 percent on price competitiveness.